Gara Jalqabaatti › Leukemia › Tennessee
Qorannoo klinikaalii Leukemia Tennessee keessatti
Qorannoo 14 Leukemia f Tennessee keessatti hirmaatuu jiru.
Magaalota Tennessee keessatti
Takkalaa qorannoo (Ingiliffa)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 12, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 71 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07504458A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- St. Jude Children's Research Hospital, Memphis
Namoota walitti qabaa jiraSadarkaa 1
Hanga umuriin 25 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06810583Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07284433Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 13 hanga 90 · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT06533579Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT07216443A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 hanga 95 · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Sad-2024 · NCT06034275Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.